PDCD1 and neoplasm: In a xenograft model using the same tumor cell lines, they were able to show, that the anti-CD19/PD-1 secreting CAR had better anti-tumor activity than either the anti-CD19 CAR alone or the anti-CD19 CAR combined with an infused PD-1 antibody.